Hormone replacement therapy.pages

Hormone Replacement Therapy
This information sheet is to inform women of the latest research regarding Hormone
Replacement Therapy (HRT) and help each woman determine if HRT is right for her.
HRT are the female hormones - estrogen and progesterone - that a woman can take for
menopausal symptoms such as hot flushes, moodiness, insomnia, and vaginal dryness.
(Please read the handout on Menopause for further information). After reading this
update, it is very important that each woman discuss her individual case, concerns, and
questions with her health care provider. What is best for your sister or friend may not be
best for you.
The Recent Study:
The Women’s Health Initiative (WHI) is a long-term study sponsored by the National
Institute of Health (NIH) that is looking at ways to prevent heart disease, breast and colon
cancer, and osteoporosis. One arm of the study followed 16,608 healthy postmenopausal
women (with a uterus), ages 50-79. Women in this arm of the study were randomly put
into one of two groups: one group of women took Prempo (which is Premarin or
conjugated equine estrogen 0.625 mg/day and Provera or medroxyprogesterone acetate
2.5 mg/day) and the other group took placebo (sugar pill). The other arm of the study is
looking at women with no uterus and taking estrogen-only therapy. The study is designed
to assess the major benefit and risks of HRT with regard to heart disease, blood clots in
the lungs, breast cancer, colon cancer, and osteoporosis/bone fractures. Other factors,
such as reduction in hot flushes, moodiness, and vaginal dryness, are not assessed.
During the study, the data collected the first 3-4 years indicated a small increase in heart attacks, strokes, and blood clots in women taking hormones. But it was not until the 5th year of the study that the data indicated for the first time that the number of cases of invasive breast cancer in the Premarin (estrogen) and Provera (progestin) group had crossed the boundary established as a signal of increased risk. The study was halted in May 2002 with this group in the study; however, the other part of the study with the groups of women taking estrogen-only therapy and placebo continues.
Putting the Risks for Women Who Take Estrogen and Progestin as Indicated by the
WHI Study into Perspective
The data indicated that if 10,000 women take the studied HRT regimen for one year, as
compared to 10,000 women taking placebo, the following risks would occur:
-8 more women will have blood clots in the lungs -6 fewer women will have colorectal cancer The increased breast cancer risk did not appear in the first 4 years of use. Increased risk for blood clots was greatest during the first 2 years of hormone use. The reduced risk of colorectal cancer occurred after 3 years of hormone use.
Limitations of the Study
The study does not look at the benefits of HRT to relieve menopausal symptoms, such as
hot flashes, moodiness, insomnia, and vaginal dryness. For many women, these benefits
are very important! (See handout on Menopause for treatments of these symptoms).
The study used only ONE preparation of HRT (Premarin 1.625 mg/day and Provera 2.5 mg/day). The data from the WHI cannot be applied to ALL of the different HRT therapies containing estrogen and progestin, such as Estrace, Prometrium, and the HRT patch (these contain different types of estrogens and progestins). However, other HRT therapies have NOT been studied in this way, so it cannot be assumed that they are different (better or worse) than those studied. Until more studies are completed on other HRT therapies, it is recommended women using all types of HRT talk to their health care provider and weigh the risks and benefits as discussed in this update.
Applying Accounts of Risk to Individual Situation
The percentage of women in the WHI study who actually had negative effects from HRT
was small, as was the size of the risk for each individual woman taking HRT. For
example, with breast cancer, while the increase risk for the group taking HRT was 26%,
an individual woman’s increased risk for breast cancer with HRT use was less than one
tenth of the percent a year,
according to the study authors. However, this small increase in
individual risk goes up over time. In other words, the longer a woman stays on HRT, the
more risk she has for developing breast cancer – even a higher risk than would normally
occur with advancing age.
Recommendations for Women Who Want to Take HRT:
Short-term relief of menopausal symptoms:
For women taking HRT for short-term relief of menopausal symptoms, the benefits of HRT are likely to outweigh the risks.
Long-term relief of postmenopausal symptoms:
Women may find that longer-term use of HRT to relive symptoms such as vaginal dryness, hot flushes, and insomnia coupled with the proven benefits of prevention of fractures and reduction of colon cancer may outweigh the risks of HRT. Alternative treatments for these symptoms need to be discussed and an assessment of the woman’s individual risks for heart disease, stroke, and breast cancer needs to be addressed with her health care provider. Consider Alternative Treatments for Symptoms:
Lifestyle changes that can reduce (not eliminate) symptoms of menopause: Stop smoking; avoid triggers to hot flashes such as spicy foods, caffeine, and alcohol Decrease stress; exercise regularly, and wear loose clothes Other medications:
Clonidine (high blood pressure medication); particular antidepressants; and estrogen vaginal cream. -there have been few studies regarding herbal preparations and effective treatment for menopausal symptoms and the results are conflicting and inconclusive. Some women have found the following to be helpful: soy products and black cohosh (to help with hot flashes), chaste-tree or vitex (to help with loss of sexual interest and vaginal dryness), and others. Remember, many herbal preparations are not well-studied and none are regulated by the government – so you cannot be certain what or how much of an herb or contaminant you are getting in a given bottle. It is recommended you talk to your health care provider about alternative methods to relieve menopausal symptoms. Cardiac Protection:
Women who are taking or considering HRT only for the prevention of heart disease
should talk to their health care provider about other methods to lower their risks.
Women who are taking HRT only for the prevention of osteoporosis should talk to their
health care provider about their personal risks and benefits for continuing the drug
therapy. There are alternatives to long-term prevention of osteoporosis that should be
considered for these women.
Individualizing Your Care:
You need to talk with your health care provider about your particular symptoms, risk
factors, options, and the benefits that best suit your needs at this point in time. If you are
presently taking HRT, it is very important to talk to your health care provider before
changing your therapy or stopping HRT. Together, you can determine what is best for you in regard to HRT! Taking Estrogen-Only Therapy – For Women with a Hysterectomy:
So far, that arm of the WHI study continues. The same proportion of risks to benefits has
not appeared. Complete results probably will not be known until 2005. Individual
consideration should apply to these women, as well: talk to your health care provider.
NOTE: Women who have a uterus should NOT take estrogen alone – it ahs been proven
to increase risk for cancer of the uterus.
Also, if a woman had a hysterectomy and had endometriosis, she may still need
progesterone to control growth of implants. 16 cases in literature have been reported in
which malignancy developed in endometrial tissue of women when treated with
unopposed estrogen.
Birge, SJ, Gass, M, & Ravinkar, VA. (2003). The Women’s Initiative: Where do we go from here? The Female Patient, Supplement Jan 2003, 1-24.
Hendrix, SL. (2002). Summarizing the evidence. The Female Patient, Supplement Nov 2002, 32-34.
Lobo, RA. (2002). HRT and menopausal health: Clinical Implications of recent data. Baltimore, MD: The John Medicine and The Institute for John Hopkins Nursing. NAMS Report. (2003). Amended report from the NAMS Advisory on postmenopausal hormone therapy. Menopause, Zacur, H, Appling, SE, Freedman, M, & Rice, VM. (2002). health and hormones: Enhancing patient management. Baltimore, MD: John Hopkins University School of Medicine and The Institute for Hopkins Other Resources
Grady, DA. (2002). A 60 year old female trying to

Source: http://rosemark.net/patientresources/wp-content/uploads/2011/12/2012_hormone_replacement_therapy.pdf


Chapter 22 Chapin and Skeet met up with Brian and they had breakfast in a small café just a couple of blocks from their hotel and began to plan their strategy. Chapin had thought a picture of Stan might be helpful to show people and had gotten the front desk to print out three copies of the most recent one she could find, even if it was over 15 years old. Brian suggested that, since they had

Safety data sheet

SAFETY DATA SHEET Vulcan P RFU (HSE No.:7437) 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Product name PelGar International Ltd Unit 13, Newman Lane Industrial Estate, Newman Lane, Alton, Hampshire GU34 2QR Telephone Product code 2. COMPOSITION/INFORMATION ON INGREDIENTS Hazardous components Permethrin 0.25% CAS 52645-53-1 Xn; R20/2

© 2008-2018 Medical News